Senecavirus a immunogenic compositions and methods thereof

Abstract

The present invention relates to killed/inactivated and/or recombinant Senecavirus A immunogenic compositions and vaccines, and methods of preventing or treating animals in need of with such an immunogenic compositions and vaccines.

1 - 8 . (canceled) 
     
     
         9 . An antibody that specifically binds to a polypeptide of a recombinant or chemically inactivated virus comprising an amino acid sequence that: (i) is encoded by a polynucleotide comprising 99% sequence identity to SEQ ID NO: 1 and/or 95% sequence identity to SEQ ID NO:2; (ii) has an amino acid sequence of SEQ ID NO: 3; (iii) corresponds to a P1-2A-P3 polypeptide and is encoded bv a polynucleotide comprising 90% sequence identity to SEQ ID NO: 18, 20, 22, 24, 32, and/or 33; and/or (iv) has at least 90% sequence identity to SEQ ID NO: 19, 21, 23, 25, 27, and/or 29. 
     
     
         10 - 14 . (canceled) 
     
     
         15 . A method for detecting Senecavirus A (SVA) in a sample, comprising:
 (i) contacting the sample with the antibody of  claim 9 , and detecting for binding of the SVA to the antibody   
     
     
         16 . A method for diagnosing a Senecavirus A (SVA) infection in a swine, comprising
 contacting a sample from the swine with a probe specific for a nucleic acid of a recombinant or chemically inactivated virus comprising a polynucleotide, a complement of the polynucleotide, or a DNA equivalent of the polynucleotide or the polynucleotide complement, wherein the polynucleotide: (i) comprises 99% sequence identity to SEQ ID NO: 1; (ii) comprises 95% sequence identity to SEQ ID NO: 2: and/or (iii) encodes a polypeptide having an amino acid sequence of SEQ ID NO: 3;   detecting for binding of SVA to the probe: and   determining, based on the detection step, whether the swine is infected with SVA   
     
     
         17 . An immunogenic composition comprising the antibody of  claim 9  and a pharmaceutically acceptable carrier and/or excipient. 
     
     
         18 . A vaccine comprising the antibody of  claim 9  and a pharmaceutically acceptable carrier and/or excipient. 
     
     
         19 . The immunogenic composition of  claim 17  wherein the virus is Senecavirus A (SVA). 
     
     
         20 . The immunogenic composition of  claim 19  wherein the SVA is chemically inactivated. 
     
     
         21 . The vaccine of  claim 18  wherein the virus is Senecavirus A (SVA). 
     
     
         22 . The vaccine of  claim 21  wherein the SVA is chemically inactivated.